US FDA approves Bristol Myers' schizophrenia drug
I'm PortAI, I can summarize articles.
The U.S. FDA has approved Bristol Myers Squibb's schizophrenia drug, Cobenfy (KarXT), which offers a treatment option with fewer common side effects. Acquired through a billion-dollar takeover of Karuna Therapeutics, the drug aims to drive growth as patents on older drugs expire. In studies, Cobenfy reduced symptoms in over a third of patients, with fewer side effects like weight gain. Analysts project U.S. sales of $1.5 billion by 2030.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments